Yangbing Li

7PUBLICATIONS
75CO-AUTHORS
Clinical pharmacology and therapeuticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 16, 2024
Model-Informed Drug Development-Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non-Radiographic Axial Spondyloarthritis.

Dipak S Pisal, Yangbing Li, Amit Golding

|Jun 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Michael I Barbato, Diana Bradford, Yi Ren

|Aug 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.

Michael I Barbato, Jeannette Nashed, Diana Bradford

|Jun 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.

Sandra J Casak, M Naomi Horiba, Mengdie Yuan

|Jun 02, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.

Elizabeth S Duke, Diana Bradford, Michelle Marcovitz

|Apr 06, 2023
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Katie Chon, Erin Larkins, Somak Chatterjee

Pageof 2

Frequent Collaborators

5 joint publications

Pallavi S Mishra-Kalyani

5 joint publications

Richard Pazdur

4 joint publications

Harpreet Singh

4 joint publications

Youwei Bi